CN107849125A - 用于治疗靶向聚集的肽的创伤性脑损伤的方法 - Google Patents
用于治疗靶向聚集的肽的创伤性脑损伤的方法 Download PDFInfo
- Publication number
- CN107849125A CN107849125A CN201680042690.4A CN201680042690A CN107849125A CN 107849125 A CN107849125 A CN 107849125A CN 201680042690 A CN201680042690 A CN 201680042690A CN 107849125 A CN107849125 A CN 107849125A
- Authority
- CN
- China
- Prior art keywords
- peptide
- brain injury
- reagent
- traumatic brain
- individual
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 89
- 208000030886 Traumatic Brain injury Diseases 0.000 title claims abstract description 84
- 230000009529 traumatic brain injury Effects 0.000 title claims abstract description 84
- 238000000034 method Methods 0.000 title claims abstract description 47
- 230000008685 targeting Effects 0.000 title description 11
- 210000004556 brain Anatomy 0.000 claims abstract description 41
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 37
- 230000002776 aggregation Effects 0.000 claims abstract description 35
- 238000004220 aggregation Methods 0.000 claims abstract description 35
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 28
- 238000001514 detection method Methods 0.000 claims abstract description 12
- 230000000116 mitigating effect Effects 0.000 claims abstract description 10
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 230000035479 physiological effects, processes and functions Effects 0.000 claims abstract description 5
- 206010061592 cardiac fibrillation Diseases 0.000 claims description 58
- 230000002600 fibrillogenic effect Effects 0.000 claims description 58
- 208000029028 brain injury Diseases 0.000 claims description 33
- 230000006931 brain damage Effects 0.000 claims description 18
- 231100000874 brain damage Toxicity 0.000 claims description 18
- 108090000623 proteins and genes Proteins 0.000 claims description 16
- 102000011931 Nucleoproteins Human genes 0.000 claims description 12
- 108010061100 Nucleoproteins Proteins 0.000 claims description 12
- 101000854943 Enterobacteria phage T4 Valyl-tRNA ligase modifier Proteins 0.000 claims description 11
- 208000014674 injury Diseases 0.000 claims description 9
- 230000008733 trauma Effects 0.000 claims description 8
- 101710095339 Apolipoprotein E Proteins 0.000 claims description 7
- 102100029470 Apolipoprotein E Human genes 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 5
- 108700028369 Alleles Proteins 0.000 claims description 4
- 108010060215 Apolipoprotein E3 Proteins 0.000 claims description 4
- 102000008128 Apolipoprotein E3 Human genes 0.000 claims description 4
- 238000012360 testing method Methods 0.000 claims description 4
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims description 3
- 108010071619 Apolipoproteins Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000009526 moderate injury Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 210000001259 mesencephalon Anatomy 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 description 15
- 239000000523 sample Substances 0.000 description 15
- 239000000178 monomer Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 12
- 238000002965 ELISA Methods 0.000 description 10
- 238000003118 sandwich ELISA Methods 0.000 description 8
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- 108010025628 Apolipoproteins E Proteins 0.000 description 6
- 102000013918 Apolipoproteins E Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000005013 brain tissue Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 4
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000003656 tris buffered saline Substances 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 101000935035 Rattus norvegicus Integrin beta-1 Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000003722 extracellular fluid Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000001690 micro-dialysis Methods 0.000 description 3
- 238000006384 oligomerization reaction Methods 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102100021496 Insulin-degrading enzyme Human genes 0.000 description 2
- 108090000828 Insulysin Proteins 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 239000000370 acceptor Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000003050 axon Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 108010091748 peptide A Proteins 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 210000003478 temporal lobe Anatomy 0.000 description 2
- 239000004577 thatch Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- VXUGVISSBXKUEL-UHFFFAOYSA-N 2-hydroxypropanoic acid;2-oxopropanoic acid Chemical compound CC(O)C(O)=O.CC(=O)C(O)=O VXUGVISSBXKUEL-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 230000007134 Aβ oligomerisation Effects 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000022306 Cerebral injury Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 102220538768 Superoxide dismutase [Cu-Zn]_E22G_mutation Human genes 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000029224 Thoracic injury Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003440 anti-fibrillation Effects 0.000 description 1
- 230000002072 anti-mutant effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000000429 assembly Methods 0.000 description 1
- 230000000712 assembly Effects 0.000 description 1
- 230000007844 axonal damage Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 208000015294 blood coagulation disease Diseases 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000000991 decompressive effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000003181 encephalopathic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003694 hair properties Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006680 metabolic alteration Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000001202 rhombencephalon Anatomy 0.000 description 1
- 102200131541 rs121912450 Human genes 0.000 description 1
- 102200158871 rs33955330 Human genes 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000002195 soluble material Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000007470 synaptic degeneration Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7047—Fibrils-Filaments-Plaque formation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562195183P | 2015-07-21 | 2015-07-21 | |
| US62/195,183 | 2015-07-21 | ||
| US201662288813P | 2016-01-29 | 2016-01-29 | |
| US62/288,813 | 2016-01-29 | ||
| PCT/IB2016/054318 WO2017013599A1 (en) | 2015-07-21 | 2016-07-20 | Method for treatment of traumatic brain injury targeting aggregated peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107849125A true CN107849125A (zh) | 2018-03-27 |
Family
ID=56550266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680042690.4A Pending CN107849125A (zh) | 2015-07-21 | 2016-07-20 | 用于治疗靶向聚集的肽的创伤性脑损伤的方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11327080B2 (enExample) |
| EP (1) | EP3325506A1 (enExample) |
| JP (2) | JP2018522891A (enExample) |
| CN (1) | CN107849125A (enExample) |
| AU (1) | AU2016295650A1 (enExample) |
| CA (1) | CA2991856A1 (enExample) |
| WO (1) | WO2017013599A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| EP3452508A1 (en) | 2016-05-02 | 2019-03-13 | Prothena Biosciences Limited | Antibodies recognizing tau |
| US10752679B2 (en) | 2016-05-02 | 2020-08-25 | Prothena Biosciences Limited | Tau immunotherapy |
| MX2019013045A (es) | 2017-05-02 | 2020-02-12 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| AU2020231366A1 (en) | 2019-03-03 | 2021-08-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006069081A2 (en) * | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
| CN101421303A (zh) * | 2006-03-23 | 2009-04-29 | 生命北极神经科学公司 | 改进的初原纤维选择性抗体及其用途 |
| CN103228674A (zh) * | 2010-11-10 | 2013-07-31 | 霍夫曼-拉罗奇有限公司 | 用于神经疾病免疫疗法的方法和组合物 |
| WO2013168174A1 (en) * | 2012-05-08 | 2013-11-14 | Ramot At Tel-Aviv University Ltd. | Apoe4 antibodies for treatment of neurodegenerative conditions |
| US20150004169A1 (en) * | 2009-08-28 | 2015-01-01 | The Board Of Regents Of The University Of Texas System | Methods of Treating Brain Injury |
| WO2015035190A1 (en) * | 2013-09-05 | 2015-03-12 | Cornell University | Gene therapy for alzheimer's and other neurodegenerative diseases and conditions |
| US20150126390A1 (en) * | 2013-09-12 | 2015-05-07 | Washington University | Multiplex avidity profiling of protein aggregates |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1257584T1 (de) * | 2000-02-24 | 2003-05-28 | Lilly Co Eli | Humanisierte antikörper, die amyloid beta peptid demarkieren |
| JP5362164B2 (ja) | 2000-07-07 | 2013-12-11 | バイオアークティック ニューロサイエンス アーベー | アルツハイマー病の予防及び治療 |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| JP2012532094A (ja) | 2009-06-29 | 2012-12-13 | バイオアークティック ニューロサイエンス アーベー | アルツハイマ病の治療および診断方法における使用のためのＮ末端切断型アミロイドβプロトフィブリル／オリゴマ |
| WO2011026031A1 (en) | 2009-08-28 | 2011-03-03 | The Board Of Regents Of The University Of Texas System | Antibodies that bind tau oligomers |
| CN110655573B (zh) | 2010-02-26 | 2023-07-18 | 生命北极神经科学公司 | 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用 |
| WO2014089500A1 (en) * | 2012-12-07 | 2014-06-12 | Biogen Idec International Neuroscience Gmbh | A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES |
| JO3537B1 (ar) * | 2014-07-10 | 2020-07-05 | Bioarctic Neuroscience Ab | أجسام مضادة لييفية أولية لاميلويد بيتا الببتيد ab المحسنة |
-
2016
- 2016-07-20 EP EP16742413.4A patent/EP3325506A1/en not_active Ceased
- 2016-07-20 CN CN201680042690.4A patent/CN107849125A/zh active Pending
- 2016-07-20 CA CA2991856A patent/CA2991856A1/en not_active Abandoned
- 2016-07-20 JP JP2018503215A patent/JP2018522891A/ja active Pending
- 2016-07-20 WO PCT/IB2016/054318 patent/WO2017013599A1/en not_active Ceased
- 2016-07-20 AU AU2016295650A patent/AU2016295650A1/en not_active Abandoned
- 2016-07-20 US US15/746,283 patent/US11327080B2/en active Active
-
2022
- 2022-05-13 JP JP2022079211A patent/JP2022113682A/ja active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006069081A2 (en) * | 2004-12-22 | 2006-06-29 | Washington University In St. Louis | USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY |
| CN101421303A (zh) * | 2006-03-23 | 2009-04-29 | 生命北极神经科学公司 | 改进的初原纤维选择性抗体及其用途 |
| US20150004169A1 (en) * | 2009-08-28 | 2015-01-01 | The Board Of Regents Of The University Of Texas System | Methods of Treating Brain Injury |
| CN103228674A (zh) * | 2010-11-10 | 2013-07-31 | 霍夫曼-拉罗奇有限公司 | 用于神经疾病免疫疗法的方法和组合物 |
| WO2013168174A1 (en) * | 2012-05-08 | 2013-11-14 | Ramot At Tel-Aviv University Ltd. | Apoe4 antibodies for treatment of neurodegenerative conditions |
| WO2015035190A1 (en) * | 2013-09-05 | 2015-03-12 | Cornell University | Gene therapy for alzheimer's and other neurodegenerative diseases and conditions |
| US20150126390A1 (en) * | 2013-09-12 | 2015-05-07 | Washington University | Multiplex avidity profiling of protein aggregates |
Non-Patent Citations (3)
| Title |
|---|
| MAGNONI SANDRA等: "New perspectives on amyloid beta dynamics after acute brain injury", 《ARCHIVES OF NEUROLOGY》 * |
| STINA TUCKERA等: "The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice", 《JOURNAL OF ALZHEIMER"S DISEASE》 * |
| 张赛等主编: "《现代神经创伤及神经外科危重症》", 30 November 2010 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20180209994A1 (en) | 2018-07-26 |
| WO2017013599A1 (en) | 2017-01-26 |
| EP3325506A1 (en) | 2018-05-30 |
| CA2991856A1 (en) | 2017-01-26 |
| AU2016295650A1 (en) | 2018-01-25 |
| JP2022113682A (ja) | 2022-08-04 |
| US11327080B2 (en) | 2022-05-10 |
| JP2018522891A (ja) | 2018-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gasparotto et al. | Receptor for advanced glycation end products mediates sepsis-triggered amyloid-β accumulation, Tau phosphorylation, and cognitive impairment | |
| Zhao et al. | β2-Microglobulin coaggregates with Aβ and contributes to amyloid pathology and cognitive deficits in Alzheimer’s disease model mice | |
| Fang et al. | CD36-mediated hematoma absorption following intracerebral hemorrhage: negative regulation by TLR4 signaling | |
| Zhang et al. | Endoplasmic reticulum stress: relevance and therapeutics in central nervous system diseases | |
| Kaiser et al. | Recombinant human erythropoietin prevents the death of mice during cerebral malaria | |
| Li et al. | Astrocyte-derived TNF-α-activated platelets promote cerebral ischemia/reperfusion injury by regulating the RIP1/RIP3/AKT signaling pathway | |
| Borlongan et al. | Hibernation-like state induced by an opioid peptide protects against experimental stroke | |
| CN107849125A (zh) | 用于治疗靶向聚集的肽的创伤性脑损伤的方法 | |
| Sarkar et al. | Estrogen amelioration of Aβ-induced defects in mitochondria is mediated by mitochondrial signaling pathway involving ERβ, AKAP and Drp1 | |
| TW202116801A (zh) | 抗tau抗體及其用途 | |
| WO2020132045A1 (en) | Inhibitors of sarm1 in combination with neuroprotective agents | |
| AU2014223679B2 (en) | Treatment of central nervous system disorders by intranasal administration of immunoglobulin G | |
| Ye et al. | Serum exosomal microRNA-27-3p aggravates cerebral injury and inflammation in patients with acute cerebral infarction by targeting PPARγ | |
| US20140213526A1 (en) | Small survival-promoting/immunomodulatory peptide for treatment of brain damage, neurodegenerative disorders, and inflammatory disorders | |
| Wang et al. | Montelukast sodium protects against focal cerebral ischemic injury by regulating inflammatory reaction via promoting microglia polarization | |
| Duan et al. | Endothelial EGLN3-PKM2 signaling induces the formation of acute astrocytic barrier to alleviate immune cell infiltration after subarachnoid hemorrhage | |
| Zhang et al. | Astragaloside IV protects against autoimmune myasthenia gravis in rats via regulation of mitophagy and apoptosis | |
| Wang et al. | Intracerebroventricular administration of lupus serum induces microglia activation and leukocyte adhesion in the cerebromicrovasculature of mice | |
| CN104302666A (zh) | 周围神经的IgG刺激髓鞘再生 | |
| Yu et al. | Effect of mild hypothermia on glutamate receptor expression after status epilepticus | |
| Sung et al. | P45 forms a complex with FADD and promotes neuronal cell survival following spinal cord injury | |
| Luo et al. | Effect of inducible co-stimulatory molecule siRNA in cerebral infarction rat models | |
| Xu et al. | Spi1 aggravates neuropathic pain by modulating Clec7a-mediated neuroinflammation and microglial phagocytosis | |
| Costanza et al. | Periventricular Heterotopias: Neuroependymal Abnormalities | |
| AU2005211556A1 (en) | Method Of Modulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: Stockholm, Sweden Applicant after: BIOARCTIC AB Address before: Stockholm, Sweden Applicant before: BIOARCTIC NEUROSCIENCE AB |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180327 |